<DOC>
	<DOC>NCT02217527</DOC>
	<brief_summary>The study will assess a novel active drug vs. placebo on ability to reduce smoking and aid cessation during a one-week "practice" quit period for each condition in smokers with a high interest in quitting (i.e. crossover design). Medication effects on reducing craving, withdrawal, and cognitive impairment will help assess the mechanism to support quit smoking attempts.</brief_summary>
	<brief_title>Test of Novel Drug for Smoking Cessation</brief_title>
	<detailed_description />
	<criteria>Healthy male and female dependent smokers wanting to quit soon Use of nonsmoked nicotine products Already enrolled in cessation program. Recent alcohol or substance dependence (â‰¤ 3 months) Women who are pregnant, planning a pregnancy, or lactating; all female participants shall undergo a pregnancy test at screening and will be excluded if positive. Serious or unstable medical disorder within the past 3 months Epilepsy Current diagnosis (within last 6months) of abnormal cardiac rhythms; unstable cardiovascular disease e.g. stroke, myocardial infarction in the last 6 months Evidence impaired liver function test (LFT) Evidence of kidney failure Any subject with a history of hematological cancers examples: leukemia, lymphoma etc. Any clinically significant hematological laboratory abnormality.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>crossover</keyword>
</DOC>